美国HemoGenix 
美国HemoGenix公司成立于2000年.是一家研发型公司，在造血细胞血毒性检测领域处于世界领先地位。HemoGenix公司开发的HALOTM（Hemotoxicity Assays via Luminescence Output）技术平台（专利技术），没有采用经典的集落形成评价方法，而是根据培养细胞中的ATP含量（使用发光检测法）的变化，来评价造血细胞的增生能力或化合物对造血细胞的毒副作用。ATP含量检测在96孔板中进行，高通量、高效、快速。

HemoGenix公司推出的HALO Basic Research Kit Platform，种类多达360余种。使用这些Kit可以检测来自五个物种的（人、灵长类、猪、狗、鼠），不同来源的（脊髓、脐带血、外周血）14种不同的干细胞、祖细胞，以及前体细胞种群。此外，使用这些Kit，也可以实现两种、三种、四种，甚至八种群细胞的同时检测。

HALO Stem and Progenitor Cell Quality Control（HALO SPC QC）Kit Platform是专门为分离移植用造血干细胞的实验室及脐带血库设计的，一个96孔板可同时检出7种群细胞（HPP-SP、CFC-GEMM、BFU-E、GM-CFC、T-CFC、B-CFC），根据这7种群细胞的检出情况，可判断待移植细胞的质量。

HALO Predictive Hemotoxicity Kit Platform是在HALO SPC QC Kit Platform基础上设计的，可以预测不同剂量的药物对不同种群造血细胞的作用情况，非常适用于候选新药的筛选。

以上Kit中均含有细胞培养所需的试剂：甲基纤维素、血清组分、造血细胞生长因子，以及ATP检测所需试剂，只要备有能检测96孔板的发光计即可对靶细胞（造血细胞、研究者自备）实施监测。另有一类Kit中不含有造血细胞生长因子，以满足用户非增生目的研究的需要或用户使用自己的造血因子进行实验。

此外，HemoGenix公司还提供另一种类型的Kit：The OxyFLOW Platform，该试剂盒可使用流式细胞仪检测人及其他哺乳动物外周血、脊髓、脐带血中的DNA损伤情况。

HemoGenix® was founded in March 2000 by Ivan N. Rich, PhD, an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology. HemoGenix® was formed as a Contract Research Service Laboratory for the biotechnology and pharmaceutical industry as the only company in the world primarily specializing in stem cell hemotoxicity testing. Initially, this was performed using techniques, such as the colony-forming assays. However, it was soon realized that these assays had many disadvantages (discussed elsewhere on this website) that made it a bad technique for the industry. With the help of a Phase I SBIR grant awarded from the National Cancer Institute (NCI) in October 2001, HemoGenix® began developing, what is now the HALO® Platform, in January 2002. By March 2002, The HALO® Platform was launched as a contract service at the Society of Toxicology meeting in Nashville, TN. A Phase II SBIR grant from the NCI in Spring 2003 allowed HemoGenix® to begin the necessary validation of the HALO® Platform.

In September 2003, HemoGenix® relocated from Columbia, South Carolina to Colorado Springs, Colorado in order to expand the company, begin the HALO® validation procedure and initiate production of the HALO® Kit Platform.

The HALO® Research Kit Platform was launched at the American Society of Hematology in December 2003. At the Society of Toxicology meeting in 2004, the first HALO® Hemotoxicity Kits and the OxyFLOW™ Platform were introduced. In December 2004, at the American Society of Hematology, the HALO® Stem and Progenitor Cell - Quality Control (SPC-QC) Kits and the LUMENESC™ Kit Platform to detect Mesenchymal Stem Cells (MSC) were introduced. In March 2005, the HALO® Predictive Hemotoxicity Platform was unveiled at the Society of Toxicology. Following this, HemoGenix®, launched the LumiSTEM™ Platform and introduced the concept of "In Vitro Cross-Platform Comparative Toxicity". This was based on the ability of both LUMENESC™ and LumiSTEM™ to utilize a 384-well plate format. What was missing was the 384-well plate format for the HALO® Platform. This was introduced as the HALO®-96 SEC and and HALO®-384 HT both of which allow fully automated and high-throughput capability to detect and measure the response of lympho-hematopoietic cells. Since relocating to Colorado Springs, HemoGenix®, Inc has increased its Assay Kit Catalog to over 1,000 different items. It produces and sells HALO®, LUMENESC™, LumiSTEM™ and OxyFLOW™ Kits all over the world to biotechnology and pharmaceutical companies and academic institutions.

As of January 1, 2004, HemoGenix® converted from and LLC to an "S" Corporation.